Panupong Hansrivijit, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Acute Kidney Injury | 8 | 2020 | 1942 | 1.870 |
Why?
|
Glomerulosclerosis, Focal Segmental | 3 | 2020 | 336 | 1.640 |
Why?
|
Hepatitis E virus | 2 | 2021 | 72 | 1.410 |
Why?
|
Hepatitis E | 2 | 2021 | 76 | 1.390 |
Why?
|
Nephrosis, Lipoid | 2 | 2020 | 46 | 1.380 |
Why?
|
Renal Insufficiency, Chronic | 5 | 2023 | 2298 | 0.920 |
Why?
|
Sleep Apnea Syndromes | 3 | 2021 | 984 | 0.910 |
Why?
|
Scleroderma, Localized | 1 | 2020 | 85 | 0.680 |
Why?
|
Hypoalbuminemia | 1 | 2020 | 90 | 0.670 |
Why?
|
Plasmapheresis | 1 | 2020 | 206 | 0.660 |
Why?
|
Rhabdomyolysis | 1 | 2020 | 150 | 0.630 |
Why?
|
Kidney Transplantation | 4 | 2021 | 4262 | 0.610 |
Why?
|
Creatine Kinase | 1 | 2020 | 684 | 0.600 |
Why?
|
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2021 | 238 | 0.560 |
Why?
|
Scleroderma, Systemic | 1 | 2020 | 346 | 0.550 |
Why?
|
Fatigue | 1 | 2023 | 1557 | 0.520 |
Why?
|
Creatinine | 1 | 2020 | 1918 | 0.470 |
Why?
|
Diet, Mediterranean | 1 | 2020 | 748 | 0.430 |
Why?
|
Magnesium | 3 | 2021 | 816 | 0.410 |
Why?
|
Graft Survival | 3 | 2021 | 3887 | 0.390 |
Why?
|
Organ Transplantation | 1 | 2021 | 1176 | 0.360 |
Why?
|
Echocardiography | 1 | 2023 | 5047 | 0.350 |
Why?
|
Hospital Mortality | 6 | 2021 | 5349 | 0.290 |
Why?
|
Venous Thromboembolism | 1 | 2021 | 1882 | 0.290 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2021 | 5717 | 0.260 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2019 | 3626 | 0.210 |
Why?
|
RNA, Viral | 2 | 2021 | 2874 | 0.210 |
Why?
|
Hospitalization | 7 | 2024 | 10840 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3115 | 0.200 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3238 | 0.200 |
Why?
|
Hepatitis Antibodies | 1 | 2021 | 67 | 0.190 |
Why?
|
Myeloblastin | 1 | 2021 | 101 | 0.180 |
Why?
|
Humans | 31 | 2024 | 768171 | 0.170 |
Why?
|
Bumetanide | 1 | 2020 | 101 | 0.170 |
Why?
|
Acid-Base Imbalance | 1 | 2020 | 41 | 0.170 |
Why?
|
Incidence | 4 | 2023 | 21538 | 0.170 |
Why?
|
Magnesium Deficiency | 1 | 2020 | 48 | 0.170 |
Why?
|
Sodium Potassium Chloride Symporter Inhibitors | 1 | 2020 | 158 | 0.160 |
Why?
|
Antibodies, Antineutrophil Cytoplasmic | 1 | 2021 | 297 | 0.160 |
Why?
|
Hypocalcemia | 1 | 2020 | 205 | 0.150 |
Why?
|
Peroxidase | 1 | 2021 | 610 | 0.140 |
Why?
|
Postoperative Complications | 1 | 2020 | 15833 | 0.140 |
Why?
|
Hospice Care | 1 | 2024 | 678 | 0.140 |
Why?
|
Hypercalcemia | 1 | 2020 | 424 | 0.140 |
Why?
|
Risk Factors | 8 | 2023 | 74944 | 0.140 |
Why?
|
Lymphoproliferative Disorders | 1 | 2020 | 528 | 0.140 |
Why?
|
Phosphates | 1 | 2020 | 765 | 0.140 |
Why?
|
Chlorides | 1 | 2020 | 666 | 0.140 |
Why?
|
Kidney | 3 | 2020 | 7064 | 0.140 |
Why?
|
Immunoglobulin M | 1 | 2021 | 1528 | 0.140 |
Why?
|
Risk Adjustment | 1 | 2020 | 599 | 0.130 |
Why?
|
Heart Failure | 1 | 2020 | 11879 | 0.130 |
Why?
|
Infusions, Intravenous | 1 | 2020 | 2230 | 0.120 |
Why?
|
Dyspnea | 1 | 2023 | 1352 | 0.120 |
Why?
|
Remission Induction | 1 | 2020 | 2410 | 0.110 |
Why?
|
Prevalence | 2 | 2021 | 15869 | 0.110 |
Why?
|
Cannabis | 1 | 2020 | 446 | 0.110 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 1515 | 0.110 |
Why?
|
Male | 14 | 2024 | 364731 | 0.110 |
Why?
|
Secondary Prevention | 1 | 2020 | 1474 | 0.110 |
Why?
|
Middle Aged | 11 | 2024 | 223487 | 0.110 |
Why?
|
Aged | 10 | 2024 | 171502 | 0.100 |
Why?
|
Adolescent | 5 | 2021 | 89169 | 0.100 |
Why?
|
Patient Admission | 1 | 2020 | 1365 | 0.100 |
Why?
|
Adult | 10 | 2021 | 223646 | 0.100 |
Why?
|
Nephrotic Syndrome | 1 | 2016 | 381 | 0.100 |
Why?
|
Psoriasis | 1 | 2019 | 926 | 0.090 |
Why?
|
Graft Rejection | 2 | 2021 | 4492 | 0.090 |
Why?
|
Immunologic Factors | 1 | 2020 | 1596 | 0.090 |
Why?
|
Heart-Assist Devices | 1 | 2020 | 1292 | 0.080 |
Why?
|
Immunoglobulin G | 1 | 2021 | 4568 | 0.080 |
Why?
|
Female | 12 | 2024 | 397187 | 0.080 |
Why?
|
Young Adult | 3 | 2020 | 60066 | 0.080 |
Why?
|
Treatment Outcome | 3 | 2020 | 65379 | 0.080 |
Why?
|
Biopsy | 1 | 2020 | 6792 | 0.080 |
Why?
|
Heart Ventricles | 1 | 2020 | 3841 | 0.080 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2020 | 10763 | 0.070 |
Why?
|
Combined Modality Therapy | 1 | 2020 | 8542 | 0.070 |
Why?
|
Diagnosis, Differential | 1 | 2023 | 13013 | 0.070 |
Why?
|
Patient Discharge | 1 | 2021 | 3479 | 0.070 |
Why?
|
Hematologic Neoplasms | 1 | 2019 | 1907 | 0.070 |
Why?
|
Calcium | 1 | 2020 | 5792 | 0.070 |
Why?
|
Anti-Inflammatory Agents | 1 | 2016 | 1810 | 0.070 |
Why?
|
Sepsis | 1 | 2020 | 2608 | 0.070 |
Why?
|
Disease Progression | 1 | 2023 | 13668 | 0.060 |
Why?
|
Emergency Service, Hospital | 1 | 2024 | 7951 | 0.060 |
Why?
|
Cohort Studies | 3 | 2021 | 41753 | 0.050 |
Why?
|
Age Factors | 1 | 2020 | 18415 | 0.050 |
Why?
|
Predictive Value of Tests | 1 | 2020 | 15453 | 0.050 |
Why?
|
Retrospective Studies | 3 | 2020 | 81760 | 0.050 |
Why?
|
Immunosuppressive Agents | 1 | 2016 | 4206 | 0.050 |
Why?
|
Pandemics | 1 | 2020 | 8747 | 0.040 |
Why?
|
Aged, 80 and over | 2 | 2024 | 59626 | 0.040 |
Why?
|
Prospective Studies | 2 | 2020 | 54924 | 0.040 |
Why?
|
Odds Ratio | 2 | 2020 | 9669 | 0.040 |
Why?
|
Child, Preschool | 1 | 2020 | 42669 | 0.040 |
Why?
|
Patient Transfer | 1 | 2024 | 792 | 0.030 |
Why?
|
Logistic Models | 2 | 2020 | 13290 | 0.030 |
Why?
|
Child | 2 | 2020 | 80917 | 0.030 |
Why?
|
Terminal Care | 1 | 2024 | 1770 | 0.020 |
Why?
|
Length of Stay | 1 | 2024 | 6498 | 0.020 |
Why?
|
Reoperation | 1 | 2020 | 4329 | 0.020 |
Why?
|
Quality Improvement | 1 | 2024 | 3857 | 0.020 |
Why?
|
Inpatients | 1 | 2020 | 2566 | 0.020 |
Why?
|
Hospitals | 1 | 2021 | 3886 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2020 | 3941 | 0.020 |
Why?
|
Comorbidity | 1 | 2020 | 10590 | 0.020 |
Why?
|
Databases, Factual | 1 | 2020 | 8080 | 0.010 |
Why?
|
United States | 2 | 2020 | 73039 | 0.010 |
Why?
|
Risk Assessment | 1 | 2020 | 24318 | 0.010 |
Why?
|